

We don't have reliable staging data to fully classify whether patients are advanced prostate cancer or not (or explanation of what they would class as advanced, though this is usually Stage III/IV). As such, this data is for all prostate patients treated at DGFT between 1st April 2015 and 31st March 2016:

Within your trust how many unique patients with Advanced Prostate Cancer (C61X) have been treated in the past 12 months?
We have treated 265 patients in the last 12 months with this Prostate Cancer, NOT split to advanced prostate (see note above)
How many patients with Advanced Prostate Cancer have received?

- Abiraterone (Zytiga)
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Enzalutamide (Xtandi)
- Radium-223 (Xofigo)
- Bicalutamide (Casodex)

Regimen	Count
Bicalutamide	41
Cabazitaxel	1
Docetaxel	2
Abiraterone	1

Within your trust how many unique patients with Hepatocellular Carcinoma (C220) have been treated in the past 12 months?

We have treated 1 patient in the last 12 months with this condition.

How many patients with with Hepatocellular Carcinoma have received?

- Bevacizumab (Avastin)
- Everolimus (Afinitor)
- Lapatinib (Tyverb)
- Sorafenib (Nexavar)
- Sunitinib (Sutent)

We have treated 0 patients with the above

Within your trust how many unique patients with Gastrointestinal Stromal Tumours (C269) have been treated in the past 12 months?

We have treated 9 patients in the last 12 months with this condition.

How many patients with with Gastrointestinal Stromal Tumours have received?.

- Dasatinib (Sprycel)
- Imatininb (Glivec)
- Nilotinib (Tasigna)
- Pazopanib (Votrient)
- Regorafenib (Stivarga)
- Sorafenib (Nexavar)
- Sunitinib (Sutent)

We have treated 0 patients with the above